BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10572612)

  • 1. Phase I study of Doxil and vinorelbine in metastatic breast cancer.
    Burstein HJ; Ramirez MJ; Petros WP; Clarke KD; Warmuth MA; Marcom PK; Matulonis UA; Parker LM; Harris LN; Winer EP
    Ann Oncol; 1999 Sep; 10(9):1113-6. PubMed ID: 10572612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of Doxil and vinorelbine in patients with advanced malignancies.
    Laufman LR; Spiridonidis CH; Jones JJ; Rhodes V; Rossi K; Wallace K
    Cancer Invest; 2004; 22(3):344-52. PubMed ID: 15493354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
    Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
    Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.
    Campone M; Fumoleau P; Delecroix V; Deporte-Fety R; Perrocheau G; Vernillet L; Borg-Olivier O; Louboutin JP; Bissery MC; Riva A; Azli N
    Ann Oncol; 2001 Jul; 12(7):909-18. PubMed ID: 11521794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
    Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
    Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
    Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
    Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of vinorelbine with doxorubicin/cyclophosphamide combination chemotherapy in a phase I-II study for advanced or recurrent breast cancer patients.
    Saeki T; Takashima S; Ogita M; Tabei T; Adachi I; Tamura K; Takatsuka Y; Kanda K
    Breast Cancer; 2006; 13(2):159-65. PubMed ID: 16755111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden.
    Nolè F; de Braud F; Aapro M; Minchella I; De Pas TM; Zampino MG; Monti S; Andreoni G; Goldhirsch A
    Ann Oncol; 1997 Sep; 8(9):865-70. PubMed ID: 9358936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of intravenous navelbine and doxorubicin combination in previously untreated advanced breast carcinoma.
    Pawlicki M; Rolski J; Zaluski J; Siedlecki P; Ramlau C; Tomzak P
    Oncologist; 2002; 7(3):205-9. PubMed ID: 12065792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
    Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
    Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
    Hamilton A; Biganzoli L; Coleman R; Mauriac L; Hennebert P; Awada A; Nooij M; Beex L; Piccart M; Van Hoorebeeck I; Bruning P; de Valeriola D
    Ann Oncol; 2002 Jun; 13(6):910-8. PubMed ID: 12123337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
    Hess D; Thürlimann B; Pagani O; Aebi S; Rauch D; Ballabeni P; Rufener B; Castiglione-Gertsch M; Goldhirsch A;
    Ann Oncol; 2004 Dec; 15(12):1760-5. PubMed ID: 15550580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation.
    Gebbia V; Mauceri G; Fallica G; Borsellino N; Tirrito ML; Testa A; Varvara F; Colombo A; Ferrera P
    Oncology; 2002; 63(1):23-30. PubMed ID: 12187067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
    Lorusso V; Crucitta E; Silvestris N; Guida M; Misino A; Latorre A; De Lena M
    Clin Breast Cancer; 2003 Jun; 4(2):138-41. PubMed ID: 12864942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines.
    Culine S; Roch I; Pinguet F; Romieu G; Bressolle F
    Int J Oncol; 1999 May; 14(5):999-1006. PubMed ID: 10200354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
    Kellokumpu-Lehtinen PL; Sunela K; Lehtinen I; Joensuu H; Sjöström-Mattson J;
    Clin Breast Cancer; 2006 Dec; 7(5):401-5. PubMed ID: 17239265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of fractionated vinorelbine/doxorubicin as first-line therapy for advanced breast cancer.
    Hegg R; Costa MA; Perdicaris M; Delgado GL; Cabral-Filho S; Malzyner A; Caponero R; Yamagushi N; Novaes N; Anelli A; Correa M; Nader L; Andrade C
    Curr Med Res Opin; 2001; 16(4):225-34. PubMed ID: 11268706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC).
    Bonneterre J; Chevalier B; Focan C; Mauriac L; Piccart M
    Ann Oncol; 2001 Dec; 12(12):1683-91. PubMed ID: 11843245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.